Akebia Therapeutics, Inc., a biopharmaceutical company focused on improving the lives of those affected by kidney disease, and Innovative Renal Care (IRC) have announced the nationwide availability of Vafseo® (vadadustat) across all IRC dialysis clinics. This collaboration marks a significant step in expanding access to Vafseo, an innovative treatment for anemia due to chronic kidney disease (CKD) in dialysis patients. Implemented through IRC's extensive network of over 230 dialysis centers across 28 states and Washington, D.C., the treatment is now available for patients meeting FDA-approved criteria. This partnership is expected to significantly increase the adoption of Vafseo, which has been accessible to over 55,000 patients and aims to reach more than 275,000 by the end of Q4.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9515883-en) on August 21, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.